

REGISTERED NUMBER: 05045708 (England and Wales)

FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026
FOR
FSS CLINICAL RESEARCH LIMITED

**CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026**

	Page
Company Information	1
Balance Sheet	2
Notes to the Financial Statements	3

FSS CLINICAL RESEARCH LIMITED

**COMPANY INFORMATION
FOR THE YEAR ENDED 31 MARCH 2026**

DIRECTOR: F S Smith

SECRETARY: P J M Gillingham

REGISTERED OFFICE: C/O Daggett and Company
Parkway House
Palatine Road
Manchester
M22 4DB

REGISTERED NUMBER: 05045708 (England and Wales)

ACCOUNTANTS: Daggett and Company
Chartered Accountants
Parkway House
Palatine Road
Northenden
Manchester
M22 4DB

BALANCE SHEET
31 MARCH 2026

	Notes	31.3.26 £	31.3.25 £
CURRENT ASSETS			
Debtors	5	4,422	7,187
Cash at bank		<u>195,910</u>	<u>196,110</u>
		200,332	203,297
CREDITORS			
Amounts falling due within one year	6	<u>3,504</u>	<u>2,446</u>
NET CURRENT ASSETS		<u>196,828</u>	<u>200,851</u>
TOTAL ASSETS LESS CURRENT LIABILITIES		<u>196,828</u>	<u>200,851</u>
CAPITAL AND RESERVES			
Called up share capital		100	100
Retained earnings		<u>196,728</u>	<u>200,751</u>
SHAREHOLDERS' FUNDS		<u>196,828</u>	<u>200,851</u>

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2026.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2026 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges her responsibilities for:

- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 18 September 2026 and were signed by:

F S Smith - Director

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026**

1. STATUTORY INFORMATION

FSS Clinical Research Limited is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Plant and machinery etc - 33% on cost

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 (2025 - 2).

4. TANGIBLE FIXED ASSETS

	Plant and machinery etc £
COST	
At 1 April 2025	
and 31 March 2026	<u>2,324</u>
DEPRECIATION	
At 1 April 2025	
and 31 March 2026	<u>2,324</u>
NET BOOK VALUE	
At 31 March 2026	<u><u>-</u></u>

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	31.3.26 £	31.3.25 £
Trade debtors	2,432	1,217
Other debtors	<u>1,990</u>	<u>5,970</u>
	<u><u>4,422</u></u>	<u><u>7,187</u></u>

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2026

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	31.3.26	31.3.25
	£	£
Taxation and social security	1,039	455
Other creditors	<u>2,465</u>	<u>1,991</u>
	<u>3,504</u>	<u>2,446</u>

7. DIRECTOR'S ADVANCES, CREDITS AND GUARANTEES

The following advances and credits to a director subsisted during the years ended 31 March 2026 and 31 March 2025:

	31.3.26	31.3.25
	£	£
F S Smith		
Balance outstanding at start of year	(491)	(2,634)
Amounts advanced	-	3,700
Amounts repaid	(474)	(1,557)
Amounts written off	-	-
Amounts waived	-	-
Balance outstanding at end of year	<u>(965)</u>	<u>(491)</u>

£330 (2025 £312) was paid to the director for the use of home as office.

Dividends of £5000 (2025 £6000) were paid to the director during the year.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.